PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.39%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.24%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
9.46%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 0.58%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
9.87%
EBIT growth of 9.87% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
9.85%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 3.18%. Joel Greenblatt would see if unique processes drive exceptional profitability.
20.61%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.05%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
20.62%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 6.98%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
20.62%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 6.94%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
57.10%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 9.23%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
57.10%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 16.03%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
57.10%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 10.47%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
75.35%
Net income/share CAGR near Medical - Pharmaceuticals median. Charlie Munger might see typical industry-level profit expansion over 10 years.
75.35%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 47.98%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
75.35%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 24.96%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
81.97%
Equity/share CAGR of 81.97% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
81.97%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.28%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
81.97%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 12.84%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-26.67%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-26.67%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
-26.67%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
No Data
No Data available this quarter, please select a different quarter.
4.39%
Inventory growth of 4.39% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
13.38%
Asset growth of 13.38% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.97%
BV/share growth of 5.97% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
51.23%
Debt growth of 51.23% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.